Successful completion of Phase Ib MAD clinical trial with daily dosage up to 320 mg confirming the excellent safety and tolerability profile of PRI-002
Closure of first seed investment by private equity firm Riesner Verwaltungs GmbH
2018
Acquisition of patents from Forschungszentrum Jülich
Successful completion of the first-in-human phase I SAD clinical trial with PRI-002
Start of the Phase I MAD clinical trial for PRI-002 in December 2018
2017
Founding of Priavoid
2013
Basic Research at Forschungszentrum Jülich
Research funding by Forschungszentrum Jülich | Helmholtz Gesellschaft | VW Stiftung | Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf
